Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind comparison of CMAB015 versus Cosentyx in adults with moderate to severe chronic plaque psoriasis
CTR20241880Phase 3Completed
- Sponsor
- Mabpharm Limited
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in psoriasis, sponsored by Mabpharm Limited. Started Sep 2024; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20241880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241880.